



## Cancer Gene Therapy With Non-Viral Nanocarriers

Guest Editors:

**Dr. Sophia Hatziantoniou**

Laboratory of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patras, Greece

**Dr. Eleftheria Galatou**

Department of Life and Health Sciences, School of Science and Engineering, University of Nicosia, 2417 Nicosia, Cyprus

**Dr. Elena Mourelatou**

Department of Life & Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus

Deadline for manuscript submissions:

**closed (31 October 2022)**

### Message from the Guest Editors

Dear Colleagues,

Conventional therapies for cancer include surgery, radiotherapy and chemotherapy but often cause severe side effects to patients due to the lack of specificity. As a result, new therapeutic treatments are needed with improved efficacy and reduced toxicity. One of these is gene therapy. The successful implementation of gene therapy needs carriers that can protect the genetic material and efficiently deliver it specifically to cancer cells. Various delivery systems have been developed and studied, including viral vectors and non-viral systems, such as lipoplexes, polyplexes and inorganic nanoparticles. Non-viral vectors present various advantages such as their safety, low cost, ability to carry larger genetic materials and be designed with specific properties.

In this Special Issue, we invite researchers to submit original research articles focusing on novel gene delivery strategies for cancer treatment using non-viral nanocarriers. Review articles on the latest advancements made in above-mentioned areas are also welcome.

Dr. Elena Mourelatou  
Prof. Sophia Hatziantoniou  
Dr. Eleftheria Galatou  
Guest Editors





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

Pharmaceutics Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma